SG11201901633WA - 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection - Google Patents
7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infectionInfo
- Publication number
- SG11201901633WA SG11201901633WA SG11201901633WA SG11201901633WA SG11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA
- Authority
- SG
- Singapore
- Prior art keywords
- shanghai
- building
- international
- road
- pct
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000009385 viral infection Effects 0.000 title abstract 3
- -1 7-substituted sulfonimidoylpurinone compounds Chemical class 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 244000061408 Eugenia caryophyllata Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIP0 I PCT omit VIII °nolo 010 0111011101111101 ow (10) International Publication Number WO 2018/041763 Al (51) International Patent Classification: CO7D 473/24 (2006.01) A61P 31/00 (2006.01) A61K 31/522 (2006.01) (21) International Application Number: PCT/EP2017/071514 (22) International Filing Date: 28 August 2017 (28.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2016/097140 29 August 2016 (29.08.2016) CN PCT/CN2017/092653 12 July 2017 (12.07.2017) CN (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: GAO, Lu; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). LIANG, Chungen; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). YUN, Hongy- ing; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). ZHENG, Xiufang; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). WANG, Jianping; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). MIAO, Kun; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). ZHANG, Bo; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). (74) Agent: BERNARD, Guillaume; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF It VIRUS INFECTION (57) : The present invention relates to compounds of formula (I), wherein R 1 , R and 2 N 0 NH 2 HN I 11 \":; z . / 0=S R 1 N R2 O 00 O C R 3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds as TLR7 agonists for the treatment of viral infections. 0
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016097140 | 2016-08-29 | ||
| CN2017092653 | 2017-07-12 | ||
| PCT/EP2017/071514 WO2018041763A1 (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901633WA true SG11201901633WA (en) | 2019-03-28 |
Family
ID=59738346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901633WA SG11201901633WA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| SG10202010520SA SG10202010520SA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010520SA SG10202010520SA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10233184B2 (en) |
| EP (2) | EP3865482A1 (en) |
| JP (2) | JP7013467B2 (en) |
| KR (2) | KR20220147702A (en) |
| CN (1) | CN109641904B (en) |
| AU (3) | AU2017320742B2 (en) |
| BR (1) | BR112019003519A2 (en) |
| CA (1) | CA3034148A1 (en) |
| CL (1) | CL2019000512A1 (en) |
| CO (1) | CO2019000932A2 (en) |
| CR (1) | CR20190087A (en) |
| DK (1) | DK3504210T3 (en) |
| ES (1) | ES2867849T3 (en) |
| HR (1) | HRP20210621T1 (en) |
| HU (1) | HUE053944T2 (en) |
| IL (3) | IL284255B (en) |
| MA (1) | MA46038B1 (en) |
| MX (2) | MX2019002129A (en) |
| MY (1) | MY197408A (en) |
| NZ (1) | NZ750604A (en) |
| PE (1) | PE20190476A1 (en) |
| PH (1) | PH12019500432A1 (en) |
| PL (1) | PL3504210T3 (en) |
| PT (1) | PT3504210T (en) |
| RS (1) | RS61752B1 (en) |
| RU (1) | RU2751349C2 (en) |
| SG (2) | SG11201901633WA (en) |
| SI (1) | SI3504210T1 (en) |
| TW (1) | TWI671300B (en) |
| UA (1) | UA124270C2 (en) |
| WO (1) | WO2018041763A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3294740T3 (en) * | 2015-05-08 | 2019-11-04 | H Hoffmann La Roche Ag | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of viral infection |
| SI3504210T1 (en) * | 2016-08-29 | 2021-08-31 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| AU2017326400B2 (en) * | 2016-09-13 | 2023-03-30 | F. Hoffmann-La Roche Ag | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor |
| JP7328977B2 (en) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | Novel sulfone compounds and derivatives for the treatment and prevention of viral infections |
| CN111801100B (en) * | 2018-02-28 | 2023-10-24 | 豪夫迈·罗氏有限公司 | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer |
| CN113164618A (en) | 2018-09-12 | 2021-07-23 | 希沃尔拜克治疗公司 | Methods and compositions for treating diseases with immunostimulatory conjugates |
| MX2021009496A (en) | 2019-02-08 | 2021-09-08 | Progeneer Inc | Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same. |
| WO2021067644A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN115666637A (en) | 2020-03-02 | 2023-01-31 | 蛋白科技先锋 | Nano particle simulating live pathogen based on pathogen cell wall skeleton and preparation method thereof |
| JP2023532304A (en) | 2020-07-01 | 2023-07-27 | エーアールエス ファーマシューティカルズ オペレーションズ，インク． | Anti-ASGR1 antibody conjugates and uses thereof |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| JP2023536954A (en) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | Conjugate of Toll-like Receptor 7 or 8 Agonist with Temporarily Inactivated Activation Site and Functional Drug, and Use of the Same |
| US20230346924A1 (en) | 2020-08-04 | 2023-11-02 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| WO2022063278A1 (en) * | 2020-09-27 | 2022-03-31 | 上海维申医药有限公司 | Macrocyclic tlr7 agonist, preparation method therefor, pharmaceutical composition and use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3485225D1 (en) * | 1983-08-18 | 1991-12-05 | Beecham Group Plc | ANTIVIRAL GUANINE DERIVATIVES. |
| NZ329798A (en) | 1996-07-03 | 1999-04-29 | Japan Energy Corp | Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same |
| AUPO912997A0 (en) * | 1997-09-11 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| AU732361B2 (en) * | 1997-11-28 | 2001-04-26 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compounds |
| JPH11180981A (en) * | 1997-12-19 | 1999-07-06 | Sumitomo Pharmaceut Co Ltd | Heterocyclic derivative |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| JP4189048B2 (en) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | Heterocyclic compounds |
| EP1490015B1 (en) * | 2002-03-15 | 2009-09-23 | Wayne State University | Novel 2-amino-9-((2-hydroxymethyl) cyclopropylidenemethyl) purines as antiviral agents |
| BR0314761A (en) * | 2002-09-27 | 2005-07-26 | Sumitomo Pharma | Adenine Compound and its Use |
| WO2006117670A1 (en) | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
| DE102006053049A1 (en) | 2006-11-10 | 2008-05-15 | Daimler Ag | Storage compartment with a cover |
| EA024359B1 (en) * | 2007-06-29 | 2016-09-30 | Джилид Сайэнс, Инк. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| CN101239980B (en) | 2008-02-18 | 2011-06-22 | 靳广毅 | Immune receptor regulator couplet precursor, couplet and application thereof |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| EP2491035B1 (en) * | 2009-10-22 | 2017-08-30 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US20110150836A1 (en) | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| SG11201701169XA (en) | 2014-08-15 | 2017-03-30 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Pyrrolopyrimidine compounds used as tlr7 agonist |
| DK3294740T3 (en) * | 2015-05-08 | 2019-11-04 | H Hoffmann La Roche Ag | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of viral infection |
| SI3504210T1 (en) * | 2016-08-29 | 2021-08-31 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
-
2017
- 2017-08-28 SI SI201730728T patent/SI3504210T1/en unknown
- 2017-08-28 UA UAA201903059A patent/UA124270C2/en unknown
- 2017-08-28 RS RS20210489A patent/RS61752B1/en unknown
- 2017-08-28 PE PE2019000346A patent/PE20190476A1/en unknown
- 2017-08-28 MY MYPI2019001082A patent/MY197408A/en unknown
- 2017-08-28 WO PCT/EP2017/071514 patent/WO2018041763A1/en active Application Filing
- 2017-08-28 PT PT177585270T patent/PT3504210T/en unknown
- 2017-08-28 KR KR1020227036198A patent/KR20220147702A/en not_active Application Discontinuation
- 2017-08-28 HU HUE17758527A patent/HUE053944T2/en unknown
- 2017-08-28 SG SG11201901633WA patent/SG11201901633WA/en unknown
- 2017-08-28 TW TW106129087A patent/TWI671300B/en active
- 2017-08-28 JP JP2019532184A patent/JP7013467B2/en active Active
- 2017-08-28 DK DK17758527.0T patent/DK3504210T3/en active
- 2017-08-28 PL PL17758527T patent/PL3504210T3/en unknown
- 2017-08-28 RU RU2019107957A patent/RU2751349C2/en active
- 2017-08-28 BR BR112019003519-2A patent/BR112019003519A2/en active Search and Examination
- 2017-08-28 CA CA3034148A patent/CA3034148A1/en active Pending
- 2017-08-28 KR KR1020197008982A patent/KR102459155B1/en active Application Filing
- 2017-08-28 IL IL284255A patent/IL284255B/en unknown
- 2017-08-28 ES ES17758527T patent/ES2867849T3/en active Active
- 2017-08-28 MX MX2019002129A patent/MX2019002129A/en unknown
- 2017-08-28 EP EP20207475.3A patent/EP3865482A1/en not_active Withdrawn
- 2017-08-28 EP EP17758527.0A patent/EP3504210B1/en active Active
- 2017-08-28 SG SG10202010520SA patent/SG10202010520SA/en unknown
- 2017-08-28 CR CR20190087A patent/CR20190087A/en unknown
- 2017-08-28 NZ NZ750604A patent/NZ750604A/en unknown
- 2017-08-28 MA MA46038A patent/MA46038B1/en unknown
- 2017-08-28 CN CN201780052692.6A patent/CN109641904B/en active Active
- 2017-08-28 AU AU2017320742A patent/AU2017320742B2/en active Active
- 2017-08-28 IL IL293475A patent/IL293475B1/en unknown
- 2017-08-29 US US15/689,136 patent/US10233184B2/en active Active
-
2019
- 2019-01-29 US US16/260,744 patent/US10752630B2/en active Active
- 2019-01-30 CO CONC2019/0000932A patent/CO2019000932A2/en unknown
- 2019-02-07 IL IL264710A patent/IL264710B/en unknown
- 2019-02-21 MX MX2021006902A patent/MX2021006902A/en unknown
- 2019-02-26 CL CL2019000512A patent/CL2019000512A1/en unknown
- 2019-02-27 PH PH12019500432A patent/PH12019500432A1/en unknown
-
2020
- 2020-08-24 US US17/001,572 patent/US20200385387A1/en not_active Abandoned
-
2021
- 2021-04-19 HR HRP20210621TT patent/HRP20210621T1/en unknown
- 2021-06-24 AU AU2021204303A patent/AU2021204303B2/en active Active
-
2022
- 2022-01-17 JP JP2022004832A patent/JP7214900B2/en active Active
- 2022-06-30 AU AU2022204697A patent/AU2022204697A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901633WA (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201908569QA (en) | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201810594RA (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization |